Patients’ survey responses ranged from the garments cause discomfort to they alleviate discomfort. Some responses indicated patients face a possible trade-off between comfort and protection in finding the optimal support garment.
Toxicity profile and readmission rates among patients who underwent radical cystectomy and pelvic lymph node dissection following neoadjuvant pembrolizumab are in line with previously published series reporting 90-day outcomes after RC with or without neoadjuvant chemotherapy.
The Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
In a small study of patients without a history of bladder cancer who undergo radical nephroureterectomy for upper tract urothelial carcinoma, preoperative pyuria was associated with a 1.7-fold increased risk of intravesical recurrence, a study found.
In a study of patients with high-risk muscle-invasive bladder cancer, patients who received cisplatin-based neoadjuvant chemotherapy had a 3.6 times higher rate of pathologic complete response compared with those who had upfront radical cystectomy.
First-line treatment with both atezolizumab and platinum-based chemotherapy (PBC) is associated with prolonged progression-free survival vs PBC alone in patients with metastatic urothelial cancer, a study found.